2023 World Conference on Lung Cancer (Posters)-EP07.04. Real-World Data Based on EGFR Mutation Status in Early-Stage NSCLC

Pdf Summary

This study focuses on EGFR mutation status in early-stage non-small cell lung cancer (NSCLC) in an East-Asian patient population. The researchers discovered that EGFR mutations were prevalent in 50% of patients, with E19del accounting for 46.2%, L858R for 41.6%, and rare mutations for 12.2%. The study found that patients with various stages of cancer had varying rates of EGFR mutations, with stage IA1, IA2, IA3, and IB having mutations in 57.3%, 56.6%, 58.2%, and 56.1% of cases, respectively. In contrast, stage II and III cases had lower rates of EGFR mutations at 31.6% and 43.1%, respectively.<br /><br />EGFR mutations were found to be more prevalent in young age, female, never smoker, and adenocarcinoma patients. The study also revealed a difference in survival between stage IB and IIIA based on EGFR mutation status. Additionally, several genes, including KRAS, ALK, CDKN2A, and SOX2, exhibited differential expression between the EGFR mutant and EGFR wild-type NSCLC patient groups. These genes also showed mutual exclusivity in EGFR mutant NSCLC.<br /><br />Future directions for research include analyzing the relationship between EGFR mutation status, PD-L1 status, and smoking status in greater detail. The study presented various figures illustrating the most prevalent mutated genes, the Kaplan-Meier curve of overall survival based on EGFR mutation status, and the frequency of EGFR mutation based on tumor stage. The study included data on patients' demographics, such as age, gender, smoking status, and tumor stage.<br /><br />Overall, the study provides insights into the prevalence and impact of EGFR mutations in early-stage NSCLC in an East-Asian patient population. It also highlights potential directions for future research in understanding the relation between EGFR mutation status, other molecular features, and treatment outcomes in NSCLC.

Asset Subtitle

Ji Hyung Hong

Meta Tag

Speaker Ji Hyung Hong

Topic Early-Stage NSCLC: Progress in Pathology

Keywords

EGFR mutation status

NSCLC

East-Asian patient population

E19del

L858R

cancer stages

adenocarcinoma

survival

mutated genes

tumor stage